Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
COMMENTARY
BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
Stephen BarkerDirector, AnalystEquity Research DepartmentUBS Warburg (Japan) LimitedPharmaceutical stocks are performing miserably, both in Japan and around the world. Weak pipelines, falling R&D productivity, generic competition, pricing and regulation issues are battering investor confidence, with no respite in sight. The…
To read the full story
COMMENTARY
- MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
- Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
- The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
- Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
- Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…